Abstract 285P
Background
Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) and CCRT alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma (NPC). However, the results of comparisons between them in clinical trials vary. Therefore, we designed this meta-analysis to illustrate their advantages and disadvantages in patients with locally advanced NPC.
Methods
We thoroughly searched the PubMed, EMBASE, and Cochrane Library databases and then merged the effect indicators of hazard ratios (HRs) and risk ratios (RRs) using RevMan 5.1.
Results
Seven randomized controlled trials totaling 2,319 patients were included in our research. The synthesized results showed that IC plus CCRT improved overall survival (HR=0.74, 95% CI: 0.62-0.88, P< 0.001), progression-free survival (HR=0.66, 95% CI: 0.57-0.77, P< 0.001), distant metastasis-free survival (HR=0.65, 95% CI: 0.43-0.81, P<0.001) and locoregional recurrence-free survival (HR=0.68 95%, CI: 0.54-0.86, P=0.001) versus CCRT alone. It also increased the risk of anemia, thrombocytopenia, and neutropenia during CCRT. However, the incidence of leukopenia and mucositis was similar in IC and IC plus CCRT. Furthermore, the subgroup analysis showed better survival outcomes with IC plus CCRT than with CCRT alone in the triweekly cisplatin subgroup (all P<0.01), whereas IC plus CCRT could only improve progression-free survival and locoregional recurrence-free survival in the weekly cisplatin subgroup (HR= 0.71, P=0.02; and HR=0.66, P=0.03, respectively).
Conclusions
IC plus CCRT improved survival outcomes in patients with locally advanced NPC versus CCRT. For the weekly cisplatin regimen subgroup, it did not improve remote control or progression-free survival versus CCRT alone, warranting further clarification.
Clinical trial identification
The protocol of our study has been registered with PROSPERO, and the number is CRD42018087074.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
People's Government of Yunnan Province (no grant number is applicable).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session